Risk of Post-COVID-19 Conditions Among Adolescents and Adults Who Received Nirmatrelvir-Ritonavir for Acute COVID-19: A Retrospective Cohort Study - Top-Institutions - MDSpire

Risk of Post-COVID-19 Conditions Among Adolescents and Adults Who Received Nirmatrelvir-Ritonavir for Acute COVID-19: A Retrospective Cohort Study

  • By

  • Alexandra F Dalton

  • Sarah Baca

  • Julia Raykin

  • Cria O Gregory

  • Tegan Boehmer

  • Emilia H Koumans

  • Priti R Patel

  • Pragna Patel

  • Sharon Saydah

  • September 16, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Centers for Disease Control and Prevention (CDC)
    Centers for Disease Control and Prevention (CDC)

    Atlanta, GA

    Key Differentiators

    • Infectious Diseases
    • Epidemiology
    • Public Health

  • #2

    National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID)
    National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID)

    Bethesda, MD

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Clinical Research

  • #3

    Massachusetts General Hospital (MGH) - Harvard Medical School
    Massachusetts General Hospital (MGH) - Harvard Medical School

    Boston, MA

    Key Differentiators

    • Infectious Diseases
    • Epidemiology
    • Clinical Trials

  • #4

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Epidemiology
    • Public Health

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • Clinical Research
    • Epidemiology

Original Source(s)

Risk of Post-COVID-19 Conditions Among Adolescents and Adults Who Received Nirmatrelvir-Ritonavir for Acute COVID-19: A Retrospective Cohort Study

  • by Alexandra F Dalton, Sarah Baca, Julia Raykin, Cria O Gregory, Tegan Boehmer, Emilia H Koumans, Priti R Patel, Pragna Patel, Sharon Saydah

  • September 16, 2025

Related Content

Case Report: Successful treatment of recurrent COVID-19 with intravenous immunoglobulin in a patient with rituximab-induced B-cell depletion and restoration of Fc-mediated effector functions

The CRISPR-powered Diagnostic SLEUTH

Novel DNA-guided system may support future RNA diagnostics and mutation detection

  • May 22, 2026

  • 2 min
Characterization of post-COVID syndrome by self-perceived symptom severity stratified by infection wave: beyond COVID, a prospective, multicenter cohort study in Germany